A Probiotic Preparation of Bacillus coagulans: Is It a Viable Adjunct Therapy for Relieving Symptoms of Osteoarthritis?

A Randomized, Placebo-Controlled Trial of a Patented Preparation of Bacillus coagulans as Adjunct Therapy for the Relief of Symptoms in Osteoarthritis

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000441213

Enrollment

Registered

2009-06-12

Start date

2005-07-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Certain probiotics have demonstrated the ability to lessen the symptoms of arthritis in animals and humans. This clinical trial was conducted to evaluate the effects of the probiotic Bacillus coagulan GBI-30, 6086 as adjunct therapy for the relief of symptoms of mild to moderate osteoarthritis.

Interventions

Bacillus coagulans GBI-30, 6086 is a patented strain of probiotic lactic-acid producing bacteria. It was taken in caplet form orally with water once daily for up to 60 days. Each caplet/dose contained 2 x 10 9 colony-forming units (CFUs).

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Healthy volunteers

Inclusion criteria

Adult men and women with a documented history of mild to moderate osteoarthritis for at least 12 months and had not started any new therpay within the last 3 months

Exclusion criteria

Women of child bearing age, current probiotic usage, antibiotic therapy over the last 2 weeks, no new therapy within the last 3 months, kidney and liver disease

Outcome results